Diagnostic performance of two serological assays for the detection of SARS-CoV-2 specific antibodies: surveillance after vaccination

Alba Fresco-Taboada; Marga García-Durán; Cristina Aira; Lissett López; Patricia Sastre; Lia van der Hoek; Marit J. van Gils; Philip J. M. Brouwer; Rogier W. Sanders; Barbara Holzer; Irene Zimpernikc; Eduardo López-Collazo; Patricia Muñoz; Paloma Rueda; Carmen Vela

doi:https://doi.org/10.1016/j.diagmicrobio.2022.115650

Diagnostic performance of two serological assays for the detection of SARS-CoV-2 specific antibodies: surveillance after vaccination

Alba Fresco-Taboada, Marga García-Durán, Cristina Aira, Lissett López, Patricia Sastre, Lia van der Hoek, Marit J. van Gils, Philip J. M. Brouwer, Rogier W. Sanders, Barbara Holzer, Irene Zimpernikc, Eduardo López-Collazo, Patricia Muñoz, Paloma Rueda, Carmen Vela

Research output: Contribution to journal › Article › Academic › peer-review

3 Citations (Scopus)

Abstract

Massive vaccination programs are being carried out to limit the SARS-CoV-2 pandemic that started in December 2019. Serological tests are of major importance as an indicator of circulation of the virus and to assess how vaccine-induced immunity progresses. An Enzyme-Linked Immunosorbent Assay (ELISA) and a Lateral Flow Assay (LFA) have been developed based on the SARS-CoV-2 recombinant Receptor Binding Domain (RBD) and the combination of Spike and Nucleoprotein, respectively. The validation with 1272 serum samples by comparison with INgezim COVID 19 DR showed good diagnostic performance (sensitivity: 93.2%-97.2%; specificity: 98.3%-99.3%) for detection of previous contact with SARS-CoV-2. Moreover, according to our results, these assays can help in the serosurveillance during and after vaccination, by detecting the humoral immune response as soon as 15 days postvaccination and identifying low-respondents. Hence, these tests could play a key role in the progression to a COVID-19 free world, helping to adjust future vaccination protocols.

Original language	English
Article number	115650
Journal	Diagnostic microbiology and infectious disease
Volume	102
Issue number	4
Early online date	26 Jan 2022
DOIs	https://doi.org/10.1016/j.diagmicrobio.2022.115650
Publication status	Published - Apr 2022

Keywords

COVID-19
RBD
SARS-CoV-2
Serology
Spike protein
Vaccination

Access to Document

https://doi.org/10.1016/j.diagmicrobio.2022.115650

Cite this

Fresco-Taboada, A., García-Durán, M., Aira, C., López, L., Sastre, P., van der Hoek, L., van Gils, M. J., Brouwer, P. J. M., Sanders, R. W., Holzer, B., Zimpernikc, I., López-Collazo, E., Muñoz, P., Rueda, P., & Vela, C. (2022). Diagnostic performance of two serological assays for the detection of SARS-CoV-2 specific antibodies: surveillance after vaccination. Diagnostic microbiology and infectious disease, 102(4), Article 115650. https://doi.org/10.1016/j.diagmicrobio.2022.115650

@article{5b2be20cff374aa5bb286d02696a4dca,

title = "Diagnostic performance of two serological assays for the detection of SARS-CoV-2 specific antibodies: surveillance after vaccination",

abstract = "Massive vaccination programs are being carried out to limit the SARS-CoV-2 pandemic that started in December 2019. Serological tests are of major importance as an indicator of circulation of the virus and to assess how vaccine-induced immunity progresses. An Enzyme-Linked Immunosorbent Assay (ELISA) and a Lateral Flow Assay (LFA) have been developed based on the SARS-CoV-2 recombinant Receptor Binding Domain (RBD) and the combination of Spike and Nucleoprotein, respectively. The validation with 1272 serum samples by comparison with INgezim COVID 19 DR showed good diagnostic performance (sensitivity: 93.2%-97.2%; specificity: 98.3%-99.3%) for detection of previous contact with SARS-CoV-2. Moreover, according to our results, these assays can help in the serosurveillance during and after vaccination, by detecting the humoral immune response as soon as 15 days postvaccination and identifying low-respondents. Hence, these tests could play a key role in the progression to a COVID-19 free world, helping to adjust future vaccination protocols.",

keywords = "COVID-19, RBD, SARS-CoV-2, Serology, Spike protein, Vaccination",

author = "Alba Fresco-Taboada and Marga Garc{\'i}a-Dur{\'a}n and Cristina Aira and Lissett L{\'o}pez and Patricia Sastre and {van der Hoek}, Lia and {van Gils}, {Marit J.} and Brouwer, {Philip J. M.} and Sanders, {Rogier W.} and Barbara Holzer and Irene Zimpernikc and Eduardo L{\'o}pez-Collazo and Patricia Mu{\~n}oz and Paloma Rueda and Carmen Vela",

note = "Funding Information: This work was partially funded by the Dutch government within the PPP project: RAPAPA (Rapid point of care tests to detect COVID-19 patients). Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",

year = "2022",

month = apr,

doi = "https://doi.org/10.1016/j.diagmicrobio.2022.115650",

language = "English",

volume = "102",

journal = "Diagnostic microbiology and infectious disease",

issn = "0732-8893",

publisher = "Elsevier Inc.",

number = "4",

}

Fresco-Taboada, A, García-Durán, M, Aira, C, López, L, Sastre, P, van der Hoek, L , van Gils, MJ, Brouwer, PJM, Sanders, RW, Holzer, B, Zimpernikc, I, López-Collazo, E, Muñoz, P, Rueda, P & Vela, C 2022, 'Diagnostic performance of two serological assays for the detection of SARS-CoV-2 specific antibodies: surveillance after vaccination', Diagnostic microbiology and infectious disease, vol. 102, no. 4, 115650. https://doi.org/10.1016/j.diagmicrobio.2022.115650

TY - JOUR

T1 - Diagnostic performance of two serological assays for the detection of SARS-CoV-2 specific antibodies

T2 - surveillance after vaccination

AU - Fresco-Taboada, Alba

AU - García-Durán, Marga

AU - Aira, Cristina

AU - López, Lissett

AU - Sastre, Patricia

AU - van der Hoek, Lia

AU - van Gils, Marit J.

AU - Brouwer, Philip J. M.

AU - Sanders, Rogier W.

AU - Holzer, Barbara

AU - Zimpernikc, Irene

AU - López-Collazo, Eduardo

AU - Muñoz, Patricia

AU - Rueda, Paloma

AU - Vela, Carmen

N1 - Funding Information: This work was partially funded by the Dutch government within the PPP project: RAPAPA (Rapid point of care tests to detect COVID-19 patients). Publisher Copyright: © 2022 Elsevier Inc.

PY - 2022/4

Y1 - 2022/4

N2 - Massive vaccination programs are being carried out to limit the SARS-CoV-2 pandemic that started in December 2019. Serological tests are of major importance as an indicator of circulation of the virus and to assess how vaccine-induced immunity progresses. An Enzyme-Linked Immunosorbent Assay (ELISA) and a Lateral Flow Assay (LFA) have been developed based on the SARS-CoV-2 recombinant Receptor Binding Domain (RBD) and the combination of Spike and Nucleoprotein, respectively. The validation with 1272 serum samples by comparison with INgezim COVID 19 DR showed good diagnostic performance (sensitivity: 93.2%-97.2%; specificity: 98.3%-99.3%) for detection of previous contact with SARS-CoV-2. Moreover, according to our results, these assays can help in the serosurveillance during and after vaccination, by detecting the humoral immune response as soon as 15 days postvaccination and identifying low-respondents. Hence, these tests could play a key role in the progression to a COVID-19 free world, helping to adjust future vaccination protocols.

AB - Massive vaccination programs are being carried out to limit the SARS-CoV-2 pandemic that started in December 2019. Serological tests are of major importance as an indicator of circulation of the virus and to assess how vaccine-induced immunity progresses. An Enzyme-Linked Immunosorbent Assay (ELISA) and a Lateral Flow Assay (LFA) have been developed based on the SARS-CoV-2 recombinant Receptor Binding Domain (RBD) and the combination of Spike and Nucleoprotein, respectively. The validation with 1272 serum samples by comparison with INgezim COVID 19 DR showed good diagnostic performance (sensitivity: 93.2%-97.2%; specificity: 98.3%-99.3%) for detection of previous contact with SARS-CoV-2. Moreover, according to our results, these assays can help in the serosurveillance during and after vaccination, by detecting the humoral immune response as soon as 15 days postvaccination and identifying low-respondents. Hence, these tests could play a key role in the progression to a COVID-19 free world, helping to adjust future vaccination protocols.

KW - COVID-19

KW - RBD

KW - SARS-CoV-2

KW - Serology

KW - Spike protein

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=85125115958&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/j.diagmicrobio.2022.115650

DO - https://doi.org/10.1016/j.diagmicrobio.2022.115650

M3 - Article

C2 - 35218991

SN - 0732-8893

VL - 102

JO - Diagnostic microbiology and infectious disease

JF - Diagnostic microbiology and infectious disease

IS - 4

M1 - 115650

ER -

Diagnostic performance of two serological assays for the detection of SARS-CoV-2 specific antibodies: surveillance after vaccination

Abstract

Keywords

Access to Document

Other files and links

Cite this